Table 1.
Demographic and clinical characteristics of probale and definite NTM patients
| Probable (n = 28) | Definite (n = 30) | Total (n = 58) | |
|---|---|---|---|
| Age (years) | 55.8 ± 13.1 | 48.0 ± 17.9 | 51.8 ± 16.1 |
| Sex, male | 53.5% (15) | 63.3% (19) | 58.6% (34/58) |
| HIV (+) | 100% (25/25) | 100% (26/26) | 100% (51/51) |
| TB-PCR (+) | 10.7% (3/28) | 22.2% (6/27) | 16.4% (9/55) |
| AFB staining (+) | 63.0% (17/27) | 40% (12/30) | 50.9% (29/57) |
| NTM strains | |||
| Mycobacterium intracellulare | 60.7% (17) | 56.7% (17) | 58.6% (34/58) |
| Mycobacterium chelonae | 17.9% (5) | 16.7% (5) | 17.2% (10/58) |
| Mycobacterium fortuitum | 10.7% (3) | 13.3% (4) | 12.1% (7/58) |
| Mycobacterium kansasii | 10.7% (3) | 3.3% (1) | 6.9% (4/58) |
| Mycobacterium avium | 0 | 3.3% (1) | 1.7% (1/58) |
| Mycobacterium terrae | 0 | 3.3% (1) | 1.7% (1/58) |
| Mycobacterium scrofulaceum | 0 | 3.3% (1) | 1.7% (1/58) |
| DST (resistance) | |||
| Isoniazid (1 μg/ml) | 95.2% (20/21) | 100% (28/28) | 98.0% (48/49) |
| Rifampin (50 μg/ml) | 85.7% (18/21) | 92.9% (26/28) | 89.8% (44/49) |
| Streptomycin (10 μg/ml) | 90.5% (19/21) | 85.7% (24/28) | 87.8% (43/49) |
| Ethambutol (5 μg/ml) | 47.6% (10/21) | 57.1% (16/28) | 53.1% (26/49) |
| Firsty-line drugs | 42.9% (9/21) | 53.5% (15/28) | 49.0% (24/49) |
| Symptoms | |||
| Cough | 67.9% (19) | 60.0% (18) | 63.8% (37) |
| Fever | 53.6% (15) | 30.0% (9) | 41.4% (24) |
| Dyspnea | 25.0% (7) | 36.7% (11) | 31.0% (18) |
| Hemoptysis | 7.1% (2) | 10.0% (3) | 8.6% (5) |
| T-SPOT.TB (+) | 53.5% (15/28) | 53.3% (16/30) | 53.4% (31/58) |
HIV human immunodeficiency virus, TB-PCR tuberculosis-polymerase chain reaction, AFB acid fast bacilli, NTM nontuberculous mycobacteria, DST drug susceptibility test